Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Net Cash Flow (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Net Cash Flow data on record, last reported at -$17.3 million in Q3 2025.

  • For Q3 2025, Net Cash Flow rose 70.46% year-over-year to -$17.3 million; the TTM value through Sep 2025 reached -$19.5 million, up 64.05%, while the annual FY2024 figure was $14.1 million, 117.59% up from the prior year.
  • Net Cash Flow reached -$17.3 million in Q3 2025 per GOSS's latest filing, down from -$2.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $59.6 million in Q3 2022 and bottomed at -$58.5 million in Q3 2024.
  • Average Net Cash Flow over 4 years is -$11.6 million, with a median of -$17.3 million recorded in 2025.
  • Peak YoY movement for Net Cash Flow: soared 270.18% in 2024, then tumbled 351.73% in 2025.
  • A 4-year view of Net Cash Flow shows it stood at -$42.1 million in 2022, then fell by 20.3% to -$50.7 million in 2023, then surged by 134.99% to $17.7 million in 2024, then plummeted by 197.44% to -$17.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$17.3 million in Q3 2025, -$2.8 million in Q2 2025, and -$17.2 million in Q1 2025.